Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

Autor: Genesca, E, Morgades, M, Gonzalez-Gil, C, Fuster-Tormo, F, Haferlach, C, Meggendorfer, M, Montesinos, P, Barba, P, Gil, C, Coll, R, Moreno, MJ, Martinez-Carballeira, D, Garcia-Cadenas, I, Vives, S, Ribera, J, Gonzalez-Campos, J, Diaz-Beya, M, Mercadal, S, Artola, MT, Cladera, A, Tormo, M, Bermudez, A, Vall-llovera, F, Martinez-Sanchez, P, Amigo, ML, Monsalvo, S, Novo, A, Cervera, M, Garcia-Guinon, A, Ciudad, J, Cervera, J, Hernandez-Rivas, JM, Granada, I, Haferlach, T, Orfao, A, Sole, F, Ribera, JM
Rok vydání: 2021
Předmět:
Zdroj: Leukemia Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
LEUKEMIA RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
ISSN: 0145-2126
Popis: The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of >3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with >3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corre-sponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying kar-yotypes with >3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), inde-pendently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Addi-tional molecular analyses of patients carrying >3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel tar-geted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
Databáze: OpenAIRE
Externí odkaz: